An innovative new treatment for tackling some of the toughest stomach cancers has shown promise in a phase 2 clinical trial, ...

According to the 2022 national cancer registration statistics, the number of gastric cancer patients was 356,507, accounting ...

A clinical trial using engineered immune cells to hunt cancer cells has reported impressive results for solid tumours, a type ...

AstraZeneca’s immunotherapy Imfinzi has proven it can help certain patients with early-stage stomach cancer, according to ...

Phase 3 trial shows trastuzumab deruxtecan extends survival by over three months in advanced HER2-positive gastric cancer and ...

Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE: AZN) have released detailed Phase III results that could help position their ...

Cancer patients given experimental treatment that programmes the body to attack rogue cells live 40 per cent longer, major research shows.

advanced, CLDN18.2-positive gastric or gastroesophageal junction cancer," the authors write. The study, led by Changsong Qi, MD, Beijing Key Laboratory of Cell & Gene Therapy for Solid Tumour ...

AstraZeneca and Daiichi Sankyo’s drug extended survival by 30% compared to a widely used regimen, further establishing its ...

Patients with newly diagnosed gastric or gastroesophageal junction (GEJ) cancer who received the PD-L1 inhibitor durvalumab ...